Tag Archives: NICE

Novartis’ Kisqali takes step back in heated market after NICE no vote

With sales of its breast cancer drug Kisqali lagging, Novartis saw an opening in the U.K. market to gain ground on its competitors. Now that door has swung shut. In draft guidance published Wednesday, the National Institute for Health and Care Excellence (NICE) chose not to recommend Kisqali (ribociclib) for treatment of women with hormone… Read More »